The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials
Open accessAbstract
Despite current established therapy, heart failure (HF) remains a leading cause of hospitalization and mortality worldwide. Novel therapeutic targets are therefore needed to improve the prognosis of patients with HF. The EMPA-REG OUTCOME trial ([Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) demonstrated significant reductions in mortality and HF hospitalization risk in patients with type 2 diabetes mellitus (T2D) and cardiovascular disease with the antihyperglycemic agent, empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor. The CANVAS trial (Canagliflozin Cardiovascular Assessment Study) subsequently reported a reduction in 3-point major adverse cardiovascular events and HF hospitalization risk. Although SGLT2 inhibition may have potential application beyond T2D, including HF, the mechanisms responsible for the cardioprotective effects of SGLT2 inhibitors remain incompletely understood. SGLT2 inhibition promotes natriuresis and osmotic diuresis, leading to plasma volume contraction and reduced preload, and decreases in blood pressure, arterial stiffness, and afterload as well, thereby improving subendocardial blood flow in patients with HF. SGLT2 inhibition is also associated with preservation of renal function. Based on data from mechanistic studies and clinical trials, large clinical trials with SGLT2 inhibitors are now investigating the potential use of SGLT2 inhibition in patients who have HF with and without T2D. Accordingly, in this review, we summarize the key pharmacodynamic effects of SGLT2 inhibitors and the clinical evidence that support the rationale for the use of SGLT2 inhibitors in patients with HF who have T2D. Because these favorable effects presumably occur independent of blood glucose lowering, we also explore the potential use of SGLT2 inhibition in patients without T2D with HF or at risk of HF, such as in patients with coronary artery disease or hypertension. Finally, we provide a detailed overview and summary of ongoing cardiovascular outcome trials with SGLT2 inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Antlanger, M., Aschauer, S., Kopecky, C., Hecking, M., Kovarik, J. J., Werzowa, J., Mascherbauer, J., Genser, B., Säemann, M. D., & Bonderman, D. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000473868 · Cited by 2,808
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31829e8776 · Cited by 2,106
Role of diabetes in congestive heart failure: The Framingham study
Kannel, W. B., Hjortland, M., & Castelli, W. P. (1974) · The American Journal of Cardiology · doi:10.1016/0002-9149(74)90089-7 · Cited by 2,090
Ronco, C., Haapio, M., House, A. A., Anavekar, N., & Bellomo, R. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.07.051 · Cited by 1,883
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Self-citationCherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Self-citationHyperglycemic Pseudohypoxia and Diabetic Complications
Williamson, J. R., Chang, K., Frangos, M., Hasan, K. S., Ido, Y., Kawamura, T., Nyengaard, J. R., Den Enden, M. V., Kilo, C., & Tilton, R. G. (1993) · Diabetes · doi:10.2337/diab.42.6.801 · Cited by 1,105
Xie, X., Atkins, E., Lv, J., Bennett, A., Neal, B., Ninomiya, T., Woodward, M., MacMahon, S., Turnbull, F., Hillis, G. S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00805-3 · Cited by 980
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure
Hillege, H. L., Nitsch, D., Pfeffer, M. A., Swedberg, K., McMurray, J. J. V., Yusuf, S., Granger, C. B., Michelson, E. L., Östergren, J., Cornel, J. H., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.580506 · Cited by 945
Fitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv728 · Cited by 907
Kosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., Norhammar, A., Birkeland, K. I., Jørgensen, M. E., Thuresson, M., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.029190 · Cited by 813
Lv, J., Neal, B., Ehteshami, P., Ninomiya, T., Woodward, M., Rodgers, A., Wang, H., MacMahon, S., Turnbull, F., Hillis, G., et al. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001293 · Cited by 777
Margulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., Mann, D. L., Whellan, D. J., Kiernan, M. S., Felker, G. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.10260 · Cited by 706
Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670
Rosenstock, J., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-1380 · Cited by 664
Baartscheer, A., Schumacher, C. A., Wüst, R. C. I., Fiolet, J. W. T., Stienen, G. J. M., Coronel, R., & Zuurbier, C. J. (2017) · Diabetologia · doi:10.1007/s00125-016-4134-x · Cited by 661
Kohan, D. E., Fioretto, P., Tang, W., & List, J. F. (2014) · Kidney International · doi:10.1038/ki.2013.356 · Cited by 652
Jorsal, A., Kistorp, C., Holmager, P., Tougaard, R. S., Nielsen, R., Hänselmann, A., Nilsson, B., Møller, J. E., Hjort, J., Rasmussen, J., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.657 · Cited by 592
Mudaliar, S., Alloju, S., & Henry, R. R. (2016) · Diabetes Care · doi:10.2337/dc16-0542 · Cited by 571
Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction
Mentz, R. J., Kelly, J. P., von Lueder, T. G., Voors, A. A., Lam, C. S. P., Cowie, M. R., Kjeldsen, K., Jankowska, E. A., Atar, D., Butler, J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.08.036 · Cited by 546
Chilton, R., Tikkanen, I., Cannon, C. P., Crowe, S., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12572 · Cited by 507
Lee, T.-M., Chang, N.-C., & Lin, S.-Z. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.035 · Cited by 504
Increased AT1 receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness
AbdAlla, S., Lother, H., el Massiery, A., & Quitterer, U. (2001) · Nature Medicine · doi:10.1038/nm0901-1003 · Cited by 496
Avosentan for Overt Diabetic Nephropathy
Mann, J. F. E., Green, D., Jamerson, K., Ruilope, L. M., Kuranoff, S. J., Littke, T., & Viberti, G. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009060593 · Cited by 492
Wu, J. H. Y., Foote, C., Blomster, J., Toyama, T., Perkovic, V., Sundström, J., & Neal, B. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00052-8 · Cited by 474
Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
Tikkanen, I., Narko, K., Zeller, C., Green, A., Salsali, A., Broedl, U. C., & Woerle, H. J. (2015) · Diabetes Care · doi:10.2337/dc14-1096 · Cited by 468
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
Ferrannini, E., & Solini, A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.243 · Cited by 458
Baker, W. L., Smyth, L. R., Riche, D. M., Bourret, E. M., Chamberlin, K. W., & White, W. B. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.01.007 · Cited by 452
Théroux, P., Chaitman, B. R., Danchin, N., Erhardt, L., Meinertz, T., Schroeder, J. S., Tognoni, G., White, H. D., Willerson, J. T., & Jessel, A. (2000) · Circulation · doi:10.1161/01.cir.102.25.3032 · Cited by 428
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
Inzucchi, S. E., Zinman, B., Wanner, C., Ferrari, R., Fitchett, D., Hantel, S., Espadero, R.-M., Woerle, H.-J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114559852 · Cited by 399
Hawley, S. A., Ford, R. J., Smith, B. K., Gowans, G. J., Mancini, S. J., Pitt, R. D., Day, E. A., Salt, I. P., Steinberg, G. R., & Hardie, D. G. (2016) · Diabetes · doi:10.2337/db16-0058 · Cited by 391
Wilding, J. P. H., Norwood, P., T'joen, C., Bastien, A., List, J. F., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc09-0517 · Cited by 363
Birkeland, K. I., Jørgensen, M. E., Carstensen, B., Persson, F., Gulseth, H. L., Thuresson, M., Fenici, P., Nathanson, D., Nyström, T., Eriksson, J. W., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30258-9 · Cited by 362
Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications
Bakris, G. L., Fonseca, V. A., Sharma, K., & Wright, E. M. (2009) · Kidney International · doi:10.1038/ki.2009.87 · Cited by 358
Neal, B., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Stein, P., Desai, M., Shaw, W., Jiang, J., Vercruysse, F., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.05.007 · Cited by 341
URic Acid and Risk Of Heart Failure: A Systematic Review and Meta-Analysis
Huang, H., Huang, B., Li, Y., Huang, Y., Li, J., Yao, H., Jing, X., Chen, J., & Wang, J. (2014) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft132 · Cited by 339
Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor
Fralick, M., Schneeweiss, S., & Patorno, E. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1701990 · Cited by 334
β-hydroxybutyrate: Much more than a metabolite
Newman, J. C., & Verdin, E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.08.009 · Cited by 326
Kohlhaas, M., Liu, T., Knopp, A., Zeller, T., Ong, M. F., Böhm, M., O'Rourke, B., & Maack, C. (2010) · Circulation · doi:10.1161/circulationaha.109.914911 · Cited by 322
Possible adverse effects of SGLT2 inhibitors on bone
Taylor, S. I., Blau, J. E., & Rother, K. I. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70227-x · Cited by 283
Habibi, J., Aroor, A. R., Sowers, J. R., Jia, G., Hayden, M. R., Garro, M., Barron, B., Mayoux, E., Rector, R. S., Whaley-Connell, A., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0489-z · Cited by 262
SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System
Fadini, G. P., Bonora, B. M., & Avogaro, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4301-8 · Cited by 242
Verma, S., Garg, A., Yan, A. T., Gupta, A. K., Al-Omran, M., Sabongui, A., Teoh, H., Mazer, C. D., & Connelly, K. A. (2016) · Diabetes Care · doi:10.2337/dc16-1312 · Cited by 232
Kraakman, M. J., Lee, M. K. S., Al-Sharea, A., Dragoljevic, D., Barrett, T. J., Montenont, E., Basu, D., Heywood, S., Kammoun, H. L., Flynn, M., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92450 · Cited by 227
Why Do SGLT2 Inhibitors Inhibit Only 30–50% of Renal Glucose Reabsorption in Humans?
Liu, J. (., Lee, T., & DeFronzo, R. A. (2012) · Diabetes · doi:10.2337/db12-0052 · Cited by 225
Persson, F., Nyström, T., Jørgensen, M. E., Carstensen, B., Gulseth, H. L., Thuresson, M., Fenici, P., Nathanson, D., Eriksson, J. W., Norhammar, A., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13077 · Cited by 212
A multicenter observational study of incretin-based drugs and heart failure
Filion, K. B., Azoulay, L., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Hu, N., Paterson, J. M., Targownik, L., Turin, T. C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506115 · Cited by 196
Self-citationSkin Sodium Concentration Correlates with Left Ventricular Hypertrophy in CKD
Schneider, M. P., Raff, U., Kopp, C., Scheppach, J. B., Toncar, S., Wanner, C., Schlieper, G., Saritas, T., Floege, J., Schmid, M., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060662 · Cited by 195
Liu, T., Takimoto, E., Dimaano, V. L., DeMazumder, D., Kettlewell, S., Smith, G., Sidor, A., Abraham, T. P., & O’Rourke, B. (2014) · Circulation Research · doi:10.1161/circresaha.115.303062 · Cited by 185
Neal, B., Perkovic, V., Matthews, D. R., Mahaffey, K. W., Fulcher, G., Meininger, G., Erondu, N., Desai, M., Shaw, W., Vercruysse, F., et al. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12829 · Cited by 174
Lytvyn, Y., Škrtić, M., Yang, G. K., Yip, P. M., Perkins, B. A., & Cherney, D. Z. I. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00555.2014 · Cited by 173
Self-citationMarx, N., & McGuire, D. K. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw110 · Cited by 165
Di Franco, A., Cantini, G., Tani, A., Coppini, R., Zecchi-Orlandini, S., Raimondi, L., Luconi, M., & Mannucci, E. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.05.032 · Cited by 163
Tang, H. L., Li, D. D., Zhang, J. J., Hsu, Y. H., Wang, T. S., Zhai, S. D., & Song, Y. Q. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12742 · Cited by 161
Škrtić, M., & Cherney, D. Z. I. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000084 · Cited by 156
Self-citationJoubert, M., Jagu, B., Montaigne, D., Marechal, X., Tesse, A., Ayer, A., Dollet, L., May, C. L., Toumaniantz, G., Manrique, A., et al. (2017) · Diabetes · doi:10.2337/db16-0733 · Cited by 153
Petrykiv, S. I., Sjöström, C. D., Greasley, P. J., Xu, J. L., Persson, F., & Heerspink, H. J. L. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10180916 · Cited by 151
Tanaka, H., Takano, K., Iijima, H., Kubo, H., Maruyama, N., Hashimoto, T., Arakawa, K., Togo, M., Inagaki, N., & Kaku, K. (2017) · Advances in Therapy · doi:10.1007/s12325-016-0457-8 · Cited by 140
SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System
Fadini, G. P., & Avogaro, A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30257-7 · Cited by 134
Rajasekeran, H., Lytvyn, Y., & Cherney, D. Z. I. (2016) · Kidney International · doi:10.1016/j.kint.2015.12.038 · Cited by 129
Self-citationLambert, R., Srodulski, S. J., Peng, X., Margulies, K. B., Despa, F., & Despa, S. I. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002183 · Cited by 119
Effects of glycaemic management on diabetic kidney disease
MacIsaac, R. J., Jerums, G., & Ekinci, E. I. (2017) · World Journal of Diabetes · doi:10.4239/wjd.v8.i5.172 · Cited by 118
Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes
Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Xiao, F., Zimpelmann, J., Woerle, H., Johansen, O. E., Broedl, U. C., von Eynatten, M., & Burns, K. D. (2014) · Kidney International · doi:10.1038/ki.2014.246 · Cited by 113
Self-citationNeal, B. C., Perkovic, V., Mahaffey, K. W., Fulcher, G., Erondu, N., Desai, M. G., Shaw, W. C., Law, G., Walton, M. K., Rosenthal, N., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12924 · Cited by 109
Heart Failure Outcomes in Clinical Trials of Glucose-Lowering Agents in Patients with Diabetes
FITCHETT, D. H., Udell, J. A., & Inzucchi, S. E. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.633 · Cited by 108
Self-citationMonami, M., Nreu, B., Zannoni, S., Lualdi, C., & Mannucci, E. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.04.017 · Cited by 106
Wang, Y., Desai, M. G., Ryan, P. B., DeFalco, F., Schuemie, M. J., Stang, P., Berlin, J. A., & Yuan, Ž. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.04.004 · Cited by 91
Sha, S., Polidori, D., Farrell, K., Ghosh, A., Natarajan, J., Vaccaro, N. M., Pinheiro, J. C., Rothenberg, P., & Plum‐Mörschel, L. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12418 · Cited by 90
Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond
Martens, P., Mathieu, C., & Verbrugge, F. H. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0522-x · Cited by 90
Townsend, R. R., Machin, I., Ren, J., Trujillo, A., Kawaguchi, M., Vijapurkar, U., Damaraju, C. V., & Pfeifer, M. (2016) · The Journal of Clinical Hypertension · doi:10.1111/jch.12747 · Cited by 85
A different view on sodium balance
Titze, J. M. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000085 · Cited by 83
EMPA-REG – the “diuretic hypothesis”
McMurray, J. J. V. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.10.012 · Cited by 83
Nyström, T., Bodegård, J., Nathanson, D., Thuresson, M., Norhammar, A., & Eriksson, J. W. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12889 · Cited by 81
Shi, X., Verma, S., Yun, J., Brand‐Arzamendi, K., Singh, K. K., Liu, X., Garg, A., Quan, A., & Wen, X. (2017) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-017-3018-9 · Cited by 76
Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes
Babu, A. R., Kim, S., & Babu, A. R. (2012) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s22545 · Cited by 75
Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes
Lovshin, J. A. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.08.242 · Cited by 74
Self-citationCherney, D. Z. I., & Udell, J. A. (2016) · Circulation · doi:10.1161/circulationaha.116.024764 · Cited by 66
Self-citationGLP-1 receptor agonists and heart failure in diabetes
Scheen, A. J. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30068-x · Cited by 66
Spectrum of Renal Diseases Associated with Extreme Forms of Insulin Resistance
Musso, C., Javor, E. D., Cochran, E. K., Balow, J. E., & Görden, P. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01271005 · Cited by 56
Monami, M., Zannoni, S., Pala, L., Silverii, G. A., Andreozzi, F., Sesti, G., & Mannucci, E. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.03.163 · Cited by 47
de Leeuw, A. E., & de Boer, R. A. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw009 · Cited by 46
Nielsen, R., Jorsal, A., Iversen, P., Tolbod, L. P., Bouchelouche, K., Sørensen, J., Harms, H. J., Flyvbjerg, A., Tarnow, L., Kistorp, C., et al. (2019) · Journal of Nuclear Cardiology · doi:10.1007/s12350-017-1000-2 · Cited by 43
Son, J. W., & Kim, S. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.5.373 · Cited by 41
Erkens, J. A., Klungel, O. H., Stolk, R. P., Spoelstra, J. A., Grobbee, D. E., & Leufkens, H. G. M. (2004) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.932 · Cited by 41
Takeuchi, T., Dohi, K., Omori, T., Moriwaki, K., Sato, Y., Nakamori, S., Fujimoto, N., Fujii, E., Yamada, N., & Ito, M. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.07.072 · Cited by 40
Heart Failure With Preserved Ejection Fraction
Mentz, R. J., Broderick, S., Shaw, L. K., Fiuzat, M., & O’Connor, C. M. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.039 · Cited by 38
Rajasekeran, H., Cherney, D. Z. I., & Lovshin, J. A. (2017) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000343 · Cited by 38
Self-citationNew and old agents in the management of diabetic nephropathy
Lytvyn, Y., Bjornstad, P., Pun, N., & Cherney, D. Z. I. (2016) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000214 · Cited by 36
Self-citationHeart failure 2016: still more questions than answers
Metra, M., Carubelli, V., Ravera, A., & Coats, A. J. S. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.10.060 · Cited by 27
Patel, P. A., Liang, L., Khazanie, P., Hammill, B. G., Fonarow, G. C., Yancy, C. W., Bhatt, D. L., Curtis, L. H., & Hernandez, A. F. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002638 · Cited by 23
Zimlichman, R. (2014) · Current Hypertension Reports · doi:10.1007/s11906-014-0479-z · Cited by 22
Perkins, B. A., Udell, J. A., & Cherney, D. Z. I. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.03.410 · Cited by 20
Self-citationOS 12-03 SGLT-2-INHIBITION WITH DAPAGLIFLOZIN REDUCES TISSUE SODIUM CONTENT
Schmieder, R. E., Ott, C., Linz, P. R., Jumar, A., Friedrich, S., Titze, J. M., Hammon, M., Uder, M., & Kistner, I. (2016) · Journal of Hypertension · doi:10.1097/01.hjh.0000500051.20830.98 · Cited by 10
Central Sympathetic Inhibition: a Neglected Approach for Treatment of Cardiac Arrhythmias?
Cagnoni, F., Destro, M., Bontempelli, E., Locatelli, G., Hering, D., & Schlaich, M. P. (2016) · Current Hypertension Reports · doi:10.1007/s11906-015-0619-0 · Cited by 7
Liraglutide in Heart Failure: Caution is Needed
Michel Komajda, N. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.707 · Cited by 6
(2014) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2014.3.0239 · Cited by 2
Cited by
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity
Jia, G., Hill, M. A., & Sowers, J. R. (2018) · Circulation Research · doi:10.1161/circresaha.117.311586 · Cited by 1,807
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999
Heart Failure With Reduced Ejection Fraction: A Review
Murphy, S. P., Ibrahim, N. E., & Januzzi, J. L. (2020) · JAMA · doi:10.1001/jama.2020.10262 · Cited by 769
Calcium Signaling and Reactive Oxygen Species in Mitochondria
Bertero, E., & Maack, C. (2018) · Circulation Research · doi:10.1161/circresaha.118.310082 · Cited by 617
Metadata
- Authors
- Lytvyn, Y., Bjornstad, P., Udell, J. A., Lovshin, J. A., & Cherney, D. Z. I.
- Venue
- Circulation
- Published
- 2017-10-24
- Volume
- 136
- Issue
- 17
- Pages
- 1643-1658
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2766617433
- Cited by
- 459
- References
- 105
- FWCI
- 31.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.